Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.

Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC.

Med Decis Making. 2000 Oct-Dec;20(4):413-22.

PMID:
11059474
2.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
3.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

4.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
5.

Donepezil. Pharmacoeconomic implications of therapy.

Foster RH, Plosker GL.

Pharmacoeconomics. 1999 Jul;16(1):99-114. Review.

PMID:
10539126
6.

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A.

Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000. Review.

PMID:
22480339
7.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

8.

The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies.

Furlong WJ, Feeny DH, Torrance GW, Barr RD.

Ann Med. 2001 Jul;33(5):375-84. Review.

PMID:
11491197
9.

Navigating patients and caregivers through the course of Alzheimer's disease.

Aupperle PM.

J Clin Psychiatry. 2006;67 Suppl 3:8-14; quiz 23. Review.

10.

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Health Technol Assess. 2001;5(1):1-137. Review.

11.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

12.
13.

A review of the psychometric properties of generic utility measures in multiple sclerosis.

Kuspinar A, Mayo NE.

Pharmacoeconomics. 2014 Aug;32(8):759-73. doi: 10.1007/s40273-014-0167-5. Review.

PMID:
24846760
14.

Alzheimer's disease and language impairments: social intervention and medical treatment.

Klimova B, Maresova P, Valis M, Hort J, Kuca K.

Clin Interv Aging. 2015 Aug 27;10:1401-7. doi: 10.2147/CIA.S89714. eCollection 2015. Review.

Supplemental Content

Support Center